The investment round was led by GV, the venture capital arm of Google’s parent company Alphabet, with additional funding from ARCH Venture Partners, F-Prime Capital, and Biomatics Capital.
Sekar Kathiresan, MD, former director of the center for genomic medicine at Massachusetts General Hospital, was named Verve’s CEO, effective in July. The company has already secured partnerships with CRISPR-focused biotech company Beam Therapeutics and Alphabet’s life sciences research subsidiary Verily, as well as MIT and Harvard University’s Broad Institute for biomedical and genomic research.
Verve’s mission is to use genetic analysis and genomic editing to discover and develop a one-time therapy that will protect adults at risk of coronary artery disease, the leading cause of death in the U.S.
More articles about health IT:
AI detects anxiety, depression in children’s speech patterns
Starbucks to adopt Microsoft’s blockchain service
IBM completes blockchain pilot with Syniverse
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
